Floatz Rating
CCC49/100
Confidence
Indicative
Sponsor
Washington University School of Medicine
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03755414CT.gov Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation | — | Completed | — | — | — |
NCT02456675CT.gov INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hodgkins Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Itacitinib (this asset) | Washington University School of Medicine | P2 | CCC · 49 |
| Cyclosporin A | City of Hope Medical Center | P3 | BBB |
| Vinblastine | M.D. Anderson Cancer Center | P4 | BBB |
| Bleomycin | National Cancer Institute (NCI) | P4 | BBB |
| Adriamycin | M.D. Anderson Cancer Center | P4 | BBB |
| Dacarbazine | M.D. Anderson Cancer Center | P4 | BBB |
| Methotrexate | Therapeutic Advances in Childhood Leukemia Consortium | P3 | BB |
| Isocyclophosphamide | St. Petersburg State Pavlov Medical University | P3 | BB |
| Prednisone | National Research Center for Hematology, Russia | P3 | BB |
+42 more in the Hodgkins Lymphoma cohort
Other indications for Itacitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myeloproliferative Neoplasm | — | P2 | CCC · 49 |
| Cancer | — | P2 | CCC · 49 |
| Neoplasm | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Itacitinib in Hodgkins Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/itacitinib-hodgkins-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →